Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants?
Author(s): Fulia F, Cordaro S, Meo P, Gitto P, Gitto E, Trimarchi G, Adelardi S, Barberi I Affiliation(s): Neonatal Intensive Care Unit, Department of Pediatrics, University of Messina, Messina, Italy. Publication date & source: 2003, Biol Neonate., 83(1):1-5. Publication type: Clinical Trial; Randomized Controlled Trial This study was carried out to determine whether the administration of antithrombin III decreases the risk of intraventricular hemorrhage in premature infants. In a randomized study, 60 infants born before 30 weeks of gestation were assigned to receive a loading dose of antithrombin III or placebo. There was no significant difference in the incidence of intraventricular hemorrhage between the antithrombin III and the placebo group (27.5 vs. 32%). Partial thromboplastin time, Quick’s prothrombin time and platelet count were also not significantly different between the 2 groups. We conclude that the administration of antithrombin III during the first 2 days of life does n
